Indiana University Research and Technology Corporation
发明人:
申请号：
EP14185102.2
公开号：
EP2913057A1
申请日:
2009.07.24
申请国别(地区):
EP
年份:
2015
代理人:
摘要：
Peptide variants corresponding to cancer specific isoform of proliferating cell nuclear antigen (caPCNA) interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. Cell-permeable caPCNA-derived peptides and their variants serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment cytotoxic effects of existing cancer therapy. These compositions are also useful for chemoprevention of cancer.
